Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090034 · ClinicalTrials.gov registry record
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
A clinical trial of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT04090034 is a study of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 50 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04090034, a study of Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Conditions Studied
Interventions
- PROCEDURE Peptide Receptor Radionuclide Therapy
Study Locations (2)
Texas
- Clinical Research Institute at Methodist Health System - Dallas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2026-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04090034
The ClinicalTrials.gov registry entry for NCT04090034 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (72% lower). The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which Peptide Receptor Radionuclide Therapy is the first listed.
NCT04090034 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04090034 about?
NCT04090034 is a clinical study titled "Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors". The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
What is the current status of trial NCT04090034?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-03-28. Estimated completion is 2026-06-28.
What conditions does trial NCT04090034 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT04090034?
The interventions under investigation include: Peptide Receptor Radionuclide Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT04090034?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04090034 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.